Home>>Signaling Pathways>> Metabolism>> PPAR>>15-deoxy-Δ-12,14-Prostaglandin J2

15-deoxy-Δ-12,14-Prostaglandin J2 (Synonyms: 15-deoxy-Δ12,14-PGJ2)

Catalog No.GC13960

15-deoxy-Δ-12,14-Prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2.

Products are for research use only. Not for human use. We do not sell to patients.

15-deoxy-Δ-12,14-Prostaglandin J2 Chemical Structure

Cas No.: 87893-55-8

Size Price Stock Qty
1mg
$398.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

15-deoxy-Δ12,14-Prostaglandin J2 (15-deoxy-Δ12,14-PGJ2) is formed from PGD2 by the elimination of two molecules of water. It binds selectively to PPARγ with an EC50 value of 2 µM in a murine chimera system.[1],[2] 15-deoxy-Δ12,14-PGJ2 is more potent than PGD2, Δ12-PGJ2, and PGJ2 in stimulating lipogenesis in C3H10T1/2 cells. The EC50 for induction of adipocyte differentiation in cultured fibroblasts is 7 µM.[1]

Reference:
[1]. Kliewer, S.A., Lenhard, J.M., Willson, T.M., et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83(5), 813-819 (1995).
[2]. Forman, B.M., Tontonoz, P., Chen, J., et al. 15-Deoxy-Δ12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83(5), 803-812 (1995).

Reviews

Review for 15-deoxy-Δ-12,14-Prostaglandin J2

Average Rating: 5 ★★★★★ (Based on Reviews and 17 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 15-deoxy-Δ-12,14-Prostaglandin J2

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.